Professional Documents
Culture Documents
TABLE 1 Activities of cefixime and AC alone and together versus ESBL-producing E. coli according to -lactamase gene contenta
Cefixime AC Cefixime–AC
No. of
ESBL group isolates MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range
Overall 64 6 ⬎64 0.50–⬎64 4 8 1.5–24 0.25 0.75 0.09–24
CTX-M-1 10 4 ⬎64 1–⬎64 4 8 3–24 0.25 0.38 0.09–16
CTX-M-1, TEM-1 9 3 8 1.5–32 6 6 4–6 0.38 0.5 0.19–0.75
CTX-M-3 1 64 6 25
CTX-M-14 11 4 8 0.50–12 4 6 2–⬎64 0.25 0.25 0.09–4
CTX-M-14, TEM-1 5 2 6 0.50–8 4 6 4–6 0.19 0.25 0.09–0.50
CTX-M-15 6 ⬎64 ⬎64 4–⬎64 6 12 3–12 0.38 0.5 0.25–0.50
CTX-M-15, TEM-1 2 8–⬎64 2–6 0.09–0.50
CTX-M-15, OXA-1 5 ⬎64 ⬎64 ⬎64 8 12 6–24 0.5 2 0.38–24
CTX-M-27, TEM-1 2 24–⬎64 4–6 0.25–0.50
CTX-M-32 2 32–⬎64 4–24 0.50–2
CTX-M-57 1 ⬎64 3 0.25
TEM-52 5 1 4 0.50–⬎64 2 4 1.5–24 0.09 0.19 0.09–12
SHV-12 5 6 12 4–16 3 4 2–4 0.19 0.25 0.19–0.38
a
Values are in micrograms per milliliter. When the number of isolates is ⬍5, only the range is given.
2540 jcm.asm.org Journal of Clinical Microbiology p. 2540 –2541 July 2012 Volume 50 Number 7
Letter to the Editor
ment. M100-S21, vol 31, no. 1. Clinical and Laboratory Standards Insti-
tute, Wayne, PA.
6. Dallenne C, Da Costa A, Decre D, Favier C, Arlet G. 2010. Development
of a set of multiplex PCR assays for the detection of genes encoding im-
portant beta-lactamases in Enterobacteriaceae. J. Antimicrob. Chemother.
65:490 – 495.
7. Drieux L, Brossier F, Sougakoff W, Jarlier V. 2008. Phenotypic detection
of extended-spectrum beta-lactamase production in Enterobacteriaceae:
review and bench guide. Clin. Microbiol. Infect. 14:90 –103.
8. European Committee on Antimicrobial Susceptibility Testing (EUCAST).
2008. Expert rules. European Committee on Antimicrobial Susceptibility
Testing, Växjö, Sweden. http://www.eucast.org/clinical_breakpoints/.
9. Guay DR. 2000. Pharmacodynamics and pharmacokinetics of cefdinir, an
oral extended spectrum cephalosporin. Pediatr. Infect. Dis. J. 19(12
Suppl):S141–S146.
10. Hoberman A, et al. 1999. Oral versus initial intravenous therapy for
urinary tract infections in young febrile children. Pediatrics 104(1 Pt 1):
tion before clinical use. The combination of cefixime and AC de- Edouard Bingen
serves clinical evaluation for the treatment of UTI due to ESBL- Philippe Bidet
producing E. coli. Université Denis Diderot
Sorbonne, Paris Cité
REFERENCES Paris, France
1. Balke C, et al. 2006. Evaluation of the E test for the assessment of synergy
of antibiotic combinations against multiresistant Pseudomonas aeruginosa André Birgy
isolates from cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. Elsa Sobral
25:25–30. Service de Microbiologie
2. Bocquet N, et al. 2012. Randomized trial of oral versus sequential IV/oral
antibiotic for acute pyelonephritis in children. Pediatrics 129(2):e269 –75. Hôpital Robert-Debré (AP-HP)
doi:10.1542/peds.2011-0814. Paris, France
3. Bolstrom A, Ardvison S, Ericson M, Karlsonn A. 1989. New in vitro
models for studying antibiotic combination using predefined antibiotics Patricia Mariani
gradient, abstr 011. Program and abstracts of the 16th International Con- Université Denis Diderot
gress of Chemotherapy, Jerusalem, Israel. Sorbonne, Paris Cité
4. Campbell JD, Lewis JS, II, McElmeel ML, Fulcher LC, Jorgensen JH. Paris, France
2012. Detection of favorable oral cephalosporin-clavulanate interactions
by in vitro disk approximation susceptibility testing of ESBL-producing
members of the Enterobacteriaceae. J. Clin. Microbiol. 50:1023–1026. Robert Cohen
5. Clinical and Laboratory Standards Institute. 2011. Performance stan- Centre Hospitalier Intercommunal de Créteil
dards for antimicrobial susceptibility testing, 20th informational supple- Créteil, France